医学
肌萎缩
慢性阻塞性肺病
共病
优势比
置信区间
内科学
子群分析
生活质量(医疗保健)
荟萃分析
多元分析
物理疗法
肺病
流行
横断面研究
逻辑回归
梅德林
风险评估
疾病严重程度
疾病负担
流行病学
老年学
可能性
作者
Yogesh Murugan,Vaibhavkumar N. Shrivastav,Hari Krishna Akurathi
标识
DOI:10.1186/s12890-026-04452-3
摘要
BACKGROUND: Sarcopenia is a critical comorbidity in chronic obstructive pulmonary disease (COPD), yet prevalence estimates in Asian populations using standardized Asian Working Group for Sarcopenia (AWGS) criteria remain uncertain. This review aimed to determine pooled sarcopenia prevalence in Asian COPD patients using AWGS criteria, compare AWGS-2014 versus AWGS-2019 estimates, and identify associated risk factors. METHODS: We systematically searched eight databases from inception to December 2024 for studies reporting sarcopenia prevalence in Asian COPD patients using AWGS-2014 or AWGS-2019 criteria. Pooled prevalence with 95% confidence intervals (CI) was calculated using random-effects meta-analysis with Freeman-Tukey double arcsine transformation. Quality was assessed using the Newcastle-Ottawa Scale. Subgroup analyses compared AWGS versions, and pooled odds ratios were calculated to examine risk factors. The review was registered with PROSPERO (CRD420251274827). RESULTS: Ten studies encompassing 2,371 COPD patients from five Asian countries were included. Eight studies used AWGS-2019, and two used AWGS-2014. Overall, the pooled sarcopenia prevalence was 31% (95% CI: 22-41%) with substantial heterogeneity (I²=89.9%). Individual study prevalence ranged from 9.5% to 52.5%. Subgroup analysis revealed no significant difference between AWGS-2014 (30%, 95% CI: 24-38%) and AWGS-2019 (31%, 95% CI: 22-42%) criteria (p = 0.916). All studies demonstrated high methodological quality (NOS scores: 8-10/10). Three independent risk factors were identified: older age (OR: 1.05 per year, 95% CI: 1.03-1.07), low BMI < 18.5 kg/m² (OR: 3.12, 95% CI: 1.98-4.92), and severe COPD stages 3-4 (OR: 2.74, 95% CI: 1.89-3.97). CONCLUSIONS: Approximately one-third of Asian COPD patients have sarcopenia, with comparable prevalence between AWGS versions. Findings support routine screening in high-risk subgroups and integrated care pathways addressing respiratory and musculoskeletal manifestations.
科研通智能强力驱动
Strongly Powered by AbleSci AI